KEGG   DRUG: Salmeterol xinafoate and fluticasone propionate
Entry
D08699            Mixture   Drug                                   
Name
Salmeterol xinafoate and fluticasone propionate;
Adoair diskus (TN);
Aerivio Spiromax (TN)
Product
ADVAIR (GlaxoSmithKline LLC), ADVAIR DISKUS (A-S Medication Solutions), ADVAIR HFA (A-S Medication Solutions), ADVAIR HFA (GlaxoSmithKline LLC), AIRDUO DIGIHALER (Teva Respiratory), AIRDUO RESPICLICK (Teva Respiratory)
  Generic
FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions), FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions), FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions), FLUTICASONE PROPIONATE AND SALMETEROL (A-S Medication Solutions), FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack), FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack), FLUTICASONE PROPIONATE AND SALMETEROL (Bryant Ranch Prepack), FLUTICASONE PROPIONATE AND SALMETEROL (Hikma Pharmaceuticals USA), FLUTICASONE PROPIONATE AND SALMETEROL (Prasco Laboratories), FLUTICASONE PROPIONATE AND SALMETEROL (Preferred Pharmaceuticals), FLUTICASONE PROPIONATE AND SALMETEROL (Proficient Rx LP), FLUTICASONE PROPIONATE AND SALMETEROL (RPK Pharmaceuticals), FLUTICASONE PROPIONATE AND SALMETEROL (Teva Pharmaceuticals USA), FLUTICASONE PROPIONATE AND SALMETEROL (Teva Pharmaceuticals USA), FLUTICASONE PROPIONATE AND SALMETEROL HFA (Prasco Laboratories), WIXELA INHUB (Mylan Pharmaceuticals), WIXELA INHUB (REMEDYREPACK)
Component
Salmeterol xinafoate [DR:D00687], Fluticasone propionate [DR:D01708]
Class
Metabolizing enzyme substrate
 DG01633  CYP3A/CYP3A4 substrate
  DG02913  CYP3A4 substrate
Remark
Therapeutic category: 2290
ATC code: R01AD58 R03AK06
Product: D08699<JP/US>
Efficacy
Antiasthmatic
  Disease
Asthma [DS:H00079]
Chronic obstructive pulmonary disease [DS:H01714]
Metabolism
Enzyme: CYP3A4 [HSA:1576]
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 R RESPIRATORY SYSTEM
  R01 NASAL PREPARATIONS
   R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
    R01AD Corticosteroids
     R01AD58 Fluticasone, combinations
      D08699  Salmeterol xinafoate and fluticasone propionate <JP/US>
  R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
   R03A ADRENERGICS, INHALANTS
    R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
     R03AK06 Salmeterol and fluticasone
      D08699  Salmeterol xinafoate and fluticasone propionate <JP/US>
USP drug classification [BR:br08302]
 Respiratory Tract/Pulmonary Agents
  Bronchodilator Combinations
   Fluticasone Propionate/ Salmeterol
    D08699  Salmeterol xinafoate and fluticasone propionate
Therapeutic category of drugs in Japan [BR:br08301]
 2  Agents affecting individual organs
  22  Respiratory organ agents
   229  Miscellaneous
    2290  Miscellaneous
     D08699  Salmeterol xinafoate and fluticasone propionate
Drug groups [BR:br08330]
 Metabolizing enzyme substrate
  DG01633  CYP3A/CYP3A4 substrate
   DG02913  CYP3A4 substrate
    D08699  Salmeterol xinafoate and fluticasone propionate
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D08699
Drug metabolizing enzymes and transporters [br08309.html]
 Drug metabolizing enzymes
  D08699
Other DBs
PubChem: 96025382
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system